Maitreya Medica.

Why is Maitreya Medicare Ltd falling/rising?

As of 08-Jul, Maitreya Medicare Ltd's stock price is at 140.90, unchanged from the previous session, but has declined significantly by -46.02% over the past year and -35.63% year-to-date, indicating ongoing financial challenges and weak fundamentals. Despite a slight positive performance today, concerns remain due to a lack of recent results and substantial losses, making the stock risky for investors.

As of 08-Jul, Maitreya Medicare Ltd's stock price is currently at 140.90, showing no change from the previous trading session. The stock has experienced a significant decline over the past year, with a return of -46.02%, which indicates a substantial drop in value. This decline is compounded by a year-to-date decrease of -35.63%, suggesting ongoing challenges for the company.<BR><BR>Despite a slight positive performance today, where the stock outperformed its sector by 1.61%, the overall long-term fundamentals remain weak. The company has not declared results in the last six months, raising concerns about its financial health. Key indicators such as the Return on Equity (average of 5.47%) reflect low profitability, and the latest quarterly figures show a significant loss, with a Profit After Tax (PAT) of Rs -0.89 crore, which has fallen by -166.8%. Additionally, the operating profit to net sales ratio is at its lowest, recorded at -7.74%.<BR><BR>Investor participation has increased, with a delivery volume of 2.8k on 07 Jul, rising by 34.62% against the 5-day average. However, the stock is considered risky compared to its historical valuations, and the overall sentiment remains negative due to the substantial losses reported over the past year. Thus, the combination of weak financial performance, lack of recent results, and significant declines in profitability contributes to the stock's falling trend.

Which are the latest news on Maitreya Medica.?

What does Maitreya Medica. do?

Maitreya Medicare Ltd is a micro-cap company in the hospital industry, incorporated in 2019 and recently renamed in 2023. As of March 2024, it reported net sales of 12 Cr and a net profit of -1 Cr, with a market cap of INR 104 Cr.

Overview:<BR>Maitreya Medicare Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated as Maitreya Medicare Private Limited in 2019. It underwent a name change to Maitreya Medicare Limited, with the new certificate of incorporation issued on March 30, 2023. The most recent quarterly results reported net sales and profit for March 2024.<BR><BR>Financial Snapshot:<BR>Net Sales: 12 Cr (Quarterly Results - Mar 2024)<BR>Net Profit: -1 Cr (Quarterly Results - Mar 2024)<BR>Market Cap: INR 104 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 21.00<BR>Industry P/E: 60<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.66<BR>Return on Equity: -4.37%<BR>Price to Book: 3.45<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Maitreya Medica.?

As of 10th June, Maitreya Medicare Ltd has a market capitalization of 104.00 Cr, with recent net sales of 49.48 Cr and a net profit of 4.94 Cr. The company has shareholder's funds of 32.08 Cr and total assets of 47.99 Cr.

As of 10th June, Maitreya Medicare Ltd has a market capitalization of 104.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Maitreya Medicare Ltd reported Net Sales of 49.48 Cr and a Net Profit of 4.94 Cr.<BR><BR>For the latest annual period, the company has Shareholder's Funds amounting to 32.08 Cr and Total Assets of 47.99 Cr.

Who are in the management team of Maitreya Medica.?

The management team of Maitreya Medica includes Narendra Singh Tanwar (Managing Director & CFO), Pranav Rohitbhai Thaker and Vimalkumar Natverlal Patel (Whole-time Directors), Hardik Patel and Abha Surana (Independent Directors), and Payal Mathur (Company Secretary & Compliance Officer).

The management team of Maitreya Medica includes the following individuals:<BR><BR>1. Narendra Singh Tanwar - Managing Director & CFO<BR>2. Pranav Rohitbhai Thaker - Whole-time Director<BR>3. Vimalkumar Natverlal Patel - Whole-time Director<BR>4. Hardik Patel - Independent Director<BR>5. Abha Surana - Independent Director<BR>6. Payal Mathur - Company Secretary & Compliance Officer<BR><BR>If you need more information about their roles or the company, feel free to ask!

Who are the peers of the Maitreya Medica.?

Maitreya Medica's peers include Vaidya Sane, KHFM Hospitality, Nephro Care, and others, with varying management risks and growth rates. Nephro Care has the lowest 1-year return at -44.59%, while Vaidya Sane leads with 8.17%, and Maitreya Medica's return is -45.96%.

Peers: The peers of Maitreya Medica. are Vaidya Sane, KHFM Hospitality, Nephro Care, Sangani Hospital, Aatmaj Health, Fortis Malar, Abate As Indust, Shanmuga Hos., Aashka Hospitals, and Soni Medicare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Nephro Care and Shanmuga Hos., while Average management risk is found at Vaidya Sane and Aatmaj Health, and the rest have Below Average management risk. Growth is Excellent at Nephro Care and Sangani Hospital, Average at Vaidya Sane and Aatmaj Health, while the rest exhibit Below Average growth. Good capital structure is noted at Nephro Care, Sangani Hospital, and Aatmaj Health, while the rest have Below Average or Average capital structures.<BR><BR>Return Snapshot: Nephro Care has the lowest 1-year return at -44.59%, while Vaidya Sane has the highest at 8.17%. Maitreya Medica.'s 1-year return of -45.96% is lower than both. Additionally, peers such as KHFM Hospitality, Nephro Care, Sangani Hospital, and others have negative six-month returns.

Should I buy, sell or hold Maitreya Medicare Ltd?

How has been the historical performance of Maitreya Medica.?

Maitreya Medica's historical performance has shown fluctuations, with net sales declining from 49.41 Cr in Mar'22 to 46.66 Cr in Mar'25, and profits decreasing significantly, while total assets and liabilities increased from 24.49 Cr to 47.99 Cr during the same period. Cash flow improved to 5.00 Cr in Mar'25 after a negative cash flow in Mar'24.

Answer:<BR>The historical performance of Maitreya Medica shows fluctuations in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Maitreya Medica's net sales decreased from 49.41 Cr in Mar'22 to 46.66 Cr in Mar'25, with a notable dip in Mar'24 at 47.80 Cr and a low of 39.38 Cr in Mar'23. Total operating income followed a similar trend, peaking in Mar'22 and declining to 46.66 Cr by Mar'25. The total expenditure, excluding depreciation, decreased from 46.05 Cr in Mar'22 to 41.80 Cr in Mar'25, which contributed to an operating profit (PBDIT) of 5.45 Cr in Mar'25, down from 7.82 Cr in Mar'23. Profit before tax also saw a decline, dropping from 5.93 Cr in Mar'23 to 3.21 Cr in Mar'25, while profit after tax fell from 4.25 Cr in Mar'23 to 1.87 Cr in Mar'25. The earnings per share (EPS) decreased from 8.57 in Mar'23 to 2.76 in Mar'25. On the balance sheet, total assets increased from 24.49 Cr in Mar'22 to 47.99 Cr in Mar'25, while total liabilities rose from 24.49 Cr to 47.99 Cr in the same period. Cash flow from operating activities improved to 5.00 Cr in Mar'25, contrasting with a negative cash flow of -2.00 Cr in Mar'24. Overall, Maitreya Medica has experienced a mixed performance with fluctuations in sales, profits, and cash flow, alongside a significant increase in total assets and liabilities.

Is Maitreya Medica. overvalued or undervalued?

As of August 28, 2025, Maitreya Medica's valuation has improved to attractive, indicating it is undervalued compared to peers like Apollo Hospitals and Max Healthcare, with a PE ratio of 94.15, an EV to EBITDA of 36.98, and a ROCE of 10.49%, while also outperforming the Sensex with a 1-week stock return of 3.55%.

As of 28 August 2025, Maitreya Medica's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 94.15, an EV to EBITDA of 36.98, and a ROCE of 10.49%. <BR><BR>In comparison with peers, Apollo Hospitals, which is also rated attractive, has a significantly lower PE ratio of 70.56, while Max Healthcare is deemed very expensive with a PE of 93.61. This suggests that Maitreya Medica may offer better value relative to its earnings potential. Notably, Maitreya Medica has outperformed the Sensex in the short term, with a 1-week stock return of 3.55% compared to a -2.32% return for the index.

What is the technical trend for Maitreya?

As of June 6, 2025, Maitreya's technical trend is mildly bearish, indicated by a bearish weekly MACD, daily moving averages, and OBV, despite a mildly bullish KST signal.

As of 6 June 2025, the technical trend for Maitreya has changed from bearish to mildly bearish. The weekly MACD remains bearish, while the daily moving averages also indicate a bearish stance. The KST shows a mildly bullish signal, but this is countered by the Dow Theory, which is mildly bearish on a weekly basis. The OBV is also mildly bearish, suggesting selling pressure. Overall, the current technical stance is mildly bearish, with key indicators such as the weekly MACD and daily moving averages driving this outlook.

Who are the top shareholders of the Maitreya?

The top shareholder of Maitreya is Narendra Singh Tanwar, holding 47.02%. Individual investors own 22.01%, with South Gujarat Shares And Sharebrokers Limited as the largest public shareholder at 2.27%, and a foreign institutional investor holding 0.01%.

The top shareholders of Maitreya include the promoters, with Narendra Singh Tanwar holding the largest share at 47.02%. There are no pledged promoter holdings, and individual investors collectively own 22.01% of the company. The highest public shareholder is South Gujarat Shares And Sharebrokers Limited, which holds 2.27%. Additionally, there is one foreign institutional investor (FII) that holds a very small stake of 0.01%.

When is the next results date for Maitreya?

No Upcoming Board Meetings

Has Maitreya declared dividend?

No Dividend History Available